Compare Tempus AI (TEM) vs Vanguard Total International Stock Index Fund ETF (VXUS) Price & Performance

Tempus AI (TEM) trades at $48.41, down 7.74% in the last 24 hours, reflecting a bearish technical signal. The company reported revenue of $1.27 billion in 2025 but a net loss of $245.03 million, with negative profitability metrics. Recent news highlights growth in AI-driven diagnostics and data services, including FDA approvals and research collaborations. The stock is trading well below the analyst consensus price target of $68.50, with a majority of analysts maintaining a Buy rating.

The outlook for TEM is a mix of high growth potential in healthcare AI and significant financial risk due to persistent losses. Investment opportunity lies in its proprietary data platform and expanding market reach, but risks include execution challenges and cash burn. Wall Street sentiment remains positive on long-term prospects, but investors should weigh the volatility against the company's unproven path to profitability.

VXUS trades at $83.07, down 0.36% with a bearish technical signal from moving averages. The ETF provides diversified international exposure across 8,700+ stocks in developed and emerging markets. Recent institutional buying includes Greenwood Gearhart increasing its position by 45.8% in Q1 2026 (SEC filing, July 20, 2026). Technical indicators show neutral oscillators with support at $82 and resistance at $84.

VXUS offers cost-effective international diversification at a 0.05% expense ratio, trading at a discount to US equities. Risks include global economic sensitivity and currency fluctuations. Analyst sentiment is mixed with some caution due to inflation concerns, but long-term value exists for investors seeking non-US exposure.